Can we Predict Disease Course with Clinical Factors? / Zsuzsanna Vegh, Zsuzsanna Kurti, Petra A. Golovics, Peter L. Lakatos
Background: The disease phenotype at diagnosis and the disease course of Crohn's disease (CD) and ulcerative colitis (UC) show remarkable heterogeneity across patients. Objective: This review aims to summarize the currently available evidence on clinical and some environmental predictive factors, which clinicians should evaluate in the everyday practice together with other laboratory and imaging data to prevent disease progression, enable a more personalized therapy, and avoid negative disease outcomes. Results: In recent population-based epidemiological and referral cohort studies, the evolution of disease phenotype of CD and UC varied significantly. Most CD and severe UC patients still require hospitalization or surgery/colectomy during follow-up. A change in the natural history of inflammatory bowel diseases (IBD) with improved outcomes in parallel with tailored positioning of aggressive immunomodulator and biological therapy has been suspected. Conclusion: According to the currently available literature, it is of major importance to refer IBD cases at risk for adverse disease outcomes as early during the disease course as possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current drug targets - 19(2018), 7, Seite 791- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vegh, Zsuzsanna [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (7 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009023615 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009023615 | ||
| 003 | DE-627 | ||
| 005 | 20231129100855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2018 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009023615 | ||
| 035 | |a (KFL)prod_DARH_0010J.sgm.2A3929037635FD5CF0AC3EB74A35686E44D92AD9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Vegh, Zsuzsanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can we Predict Disease Course with Clinical Factors? |c Zsuzsanna Vegh, Zsuzsanna Kurti, Petra A. Golovics, Peter L. Lakatos |
| 264 | 1 | |c 2018 | |
| 300 | |a 1 Online-Ressource (7 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: The disease phenotype at diagnosis and the disease course of Crohn's disease (CD) and ulcerative colitis (UC) show remarkable heterogeneity across patients. Objective: This review aims to summarize the currently available evidence on clinical and some environmental predictive factors, which clinicians should evaluate in the everyday practice together with other laboratory and imaging data to prevent disease progression, enable a more personalized therapy, and avoid negative disease outcomes. Results: In recent population-based epidemiological and referral cohort studies, the evolution of disease phenotype of CD and UC varied significantly. Most CD and severe UC patients still require hospitalization or surgery/colectomy during follow-up. A change in the natural history of inflammatory bowel diseases (IBD) with improved outcomes in parallel with tailored positioning of aggressive immunomodulator and biological therapy has been suspected. Conclusion: According to the currently available literature, it is of major importance to refer IBD cases at risk for adverse disease outcomes as early during the disease course as possible | ||
| 700 | 1 | |a Kurti, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Golovics, Petra A. |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, Peter L. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d Hilversum : Bentham Science Publ., 2000 |g 19(2018), 7, Seite 791- |h Online-Ressource |w (DE-627)KFL000006351 |w (DE-600)2044606-8 |w (DE-576)273880896 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:7 |g pages:791- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-4501&volume=19&issue=7&spage=791 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 7 |h 791- | ||